SiPhox Health is best when you want convenient at-home, finger-stick biomarker testing you can repeat without a lab visit. AMORTAL is different — it isn't a testing company. It takes results you already have and decides whether an at-home reading is enough to act on or worth confirming, then returns one ranked next action and a retest window.
SiPhox Health built a genuinely convenient way to test: an at-home, finger-stick collection kit you can do in minutes (SiPhox advertises ~5-minute collection), a broad menu of biomarkers (SiPhox advertises 50+), mail-in processing, and an app that returns personalized supplement and lifestyle recommendations with an AI assistant it calls Sai. It answers the question “what do my numbers look like, without booking a lab visit?” very well.
It is deliberately not built to answer the next question — “is this at-home reading enough to act on, or should I confirm it first?” At-home convenience is real, but not every decision should rest on a single capillary panel. That’s the gap this page is about. Below is a fair, source-backed look at what SiPhox is excellent for, and where AMORTAL fits as the decision-and-restraint layer on top. It’s educational, not medical advice.
+
Use SiPhox for the at-home data. Use AMORTAL to decide when a reading is enough, when to confirm, what to change, and when to retest.
The short version: who each is for
These two aren’t really competitors — one collects the data conveniently, the other decides what to do with it. Here’s the honest split.
Which one fits which job
SiPhox HealthBest for at-home convenienceA broad at-home biomarker panel collected by finger-stick and mailed in, with app-based supplement and lifestyle recommendations and an AI assistant (Sai). Strongest when you want convenient, repeatable testing without booking a lab visit.
AMORTALBest for deciding what to do nextNot a testing company. A longitudinal decision layer that reads whatever results you already have — from SiPhox or anywhere — and returns one ranked next action, a watchlist, a clinician-ready question, and an outcome loop. Including when to confirm a reading, or do nothing.
This isn't an "A beats B." SiPhox answers what are my numbers, conveniently; AMORTAL answers whether a reading is enough to act on — and what it should change. The strongest setup uses both.
SiPhox Health vs AMORTAL, at a glance
Tap between the two to see what each is actually responsible for.
What each one owns
Same goal — better decisions from your blood — split into the data job and the decision job.
The data layer
SiPhox runs a convenient at-home biomarker service — a finger-stick collection kit (SiPhox advertises ~5-minute collection), a broad menu (50+ advertised), mail-in processing with results in roughly 7–10 days, and app-based supplement and lifestyle recommendations with an AI assistant called Sai.
You want convenient, repeatable testing you can do at home, and a structured set of recommendations to react to. Verify the current marker count, turnaround, recommendation features and price before you buy.
The decision layer
AMORTAL doesn't collect samples. It takes your SiPhox results (or any lab's), normalises them into a memory, and produces one ranked next action, a watchlist, a clinician-ready question, and an outcome loop — with restraint built in, including when to confirm an at-home reading before acting.
You already have results and the real question is "is this enough to act on?" — what to change, what to ignore, what to confirm, and when a retest is actually worth it.
AMORTAL has no direct SiPhox integration — you bring the data in by upload or manual entry.
The comparison, row by row
| Dimension | SiPhox Health | AMORTAL |
|---|---|---|
| Best use case | Convenient at-home repeat testing | Deciding what the data should change |
| Collection method | At-home finger-stick / capillary kit (SiPhox advertises ~5-minute collection) | No draws — works from results you already have |
| Lab partner / processing | Mail-in processing; results in ~7–10 days (as advertised) | Lab-agnostic; vendor-neutral by design |
| Biomarker breadth | At-home panel (SiPhox advertises 50+) | Doesn’t test; reads whatever you bring |
| Upload existing labs | Its own at-home kit is the product | Yes — bring SiPhox or any other results in |
| Wearable integration | Not the core product | Connects labs to Oura / Whoop / Apple Watch context |
| Clinician review | AI guidance (Sai) + supplement/lifestyle recs (as advertised) | Clinician-compatible questions; not a clinician |
| Action plan depth | Personalised supplement / lifestyle recommendations (as advertised) | One ranked next best action, plus restraint |
| Retesting cadence | Per-kit / subscription cadence | Tells you when not to retest yet |
| Result trend tracking | Trends across your SiPhox kits | Longitudinal memory across providers and time |
| Abnormal-result handling | App flags + AI guidance (as advertised) | Safety-gated; routes urgent flags to a clinician, never diagnoses |
| Data portability | Your results live in the SiPhox app | Cross-provider memory you carry with you |
| Cost model | Per-kit or subscription (SiPhox advertises; verify current) | Decision layer — founding membership |
| Where AMORTAL fits | At-home reading in | → ranked decision, watchlist, and outcome loop out |
Provider rows describe what SiPhox publicly advertises as of June 2026 — pricing, marker count, turnaround and recommendation features change often, so confirm the current details on SiPhox's own pages before buying. Sources are listed at the foot of this page.
Which one fits what you actually want
| What you want | Reach for |
|---|---|
| Convenient at-home repeat testing | SiPhox Health |
| I’d rather skip a lab visit entirely | SiPhox Health |
| I have an at-home result — is it enough, or do I confirm? | AMORTAL |
| I already have results — tell me what to do next | AMORTAL |
| To know whether a one-off reading is worth acting on | AMORTAL |
| To avoid changing five things at once | AMORTAL |
| A clinician-ready question, not a treatment directive | AMORTAL |
| To track an at-home trend across kits and decide when to retest | AMORTAL |
How AMORTAL complements SiPhox Health
The model is simple: let SiPhox do the at-home collection it does well, then run the result through a decision process instead of a dashboard.
- Bring the result in. Upload your SiPhox report or enter the key markers — there's no direct integration, so you carry the data over.
- Normalise into memory. AMORTAL files each biomarker into a longitudinal record, not a one-off screen.
- Connect the context. Results are linked to your goals, symptoms, wearables, medications and constraints.
- Activate the standards. The guidelines and decision rules that actually apply to your situation switch on.
- Produce a Decision Contract. One change at a time, with the expected signal and the window written down in advance.
- Rank one Next Best Action. Not ten. The single highest-value move — which may be "confirm this first" or "do nothing yet."
- Set the watchlist. Markers worth re-checking get an expected direction and a recheck window.
- Close the loop. When the next SiPhox kit or outcome signal arrives, AMORTAL checks whether the action worked — and keeps or discards it.
A decision loop, end to end
Here’s the same flow on a single example — illustrative numbers only, not a target or a reference range.
From an at-home result to a tracked outcome
Your SiPhox at-home panel returns an out-of-range marker (say, an elevated hs-CRP — illustrative only, not a target or reference range). On a dashboard, that's a red number and a nudge to buy a supplement.
AMORTAL files it next to your prior at-home readings, your goals, your medications and your wearable trends — so it's read as a trajectory, not a single finger-stick dot.
One lever, not five. The expected signal and the window to see it are written down before anything changes — including whether this at-home reading should be confirmed first.
Framed as a clinician-ready question — "given this trend, is [one specific lever] the right first move, or should I confirm with a venous draw?" — not a treatment directive AMORTAL has no authority to give.
The marker goes on watch with an expected direction and a recheck window — so you retest when it's informative, not just because the kit is easy to reorder.
At your next SiPhox kit, AMORTAL checks: did it move as expected? If yes, the change earns its place. If not, it's dropped — no story told over capillary noise.
AMORTAL doesn't diagnose and isn't a substitute for your clinician — anything urgent goes to a professional, now.
Act on an at-home result, or confirm first?
At-home convenience makes it easy to act on every reading. Walk a single flagged marker through this before you change anything.
Act, confirm, or wait?
Is the result wildly out of range or alarming?
Is this a one-off reading, or a repeat trend across kits?
Would acting on it mean a medication-class change?
An at-home capillary panel can misread, and a big decision deserves a second measurement. Confirm with a clinician or a venous draw before you change anything — AMORTAL routes alarming results toward professional care; it never sits between you and it.
A single at-home value is a data point, not a signal. Re-test in the next window before concluding anything. This is exactly the "do nothing yet" call AMORTAL is built to make explicit.
A medication-class change isn't a self-start — even with a clean trend. Take the trend in hand to a professional and ask the question; AMORTAL frames it, it doesn't prescribe.
This is a fair place to act. Define the expected signal and the recheck window before you start — that's a Decision Contract, and it's what turns a guess into a result you can read.
Where SiPhox is strongest — and where it isn’t
In fairness to both tools:
- SiPhox is strongest when you want convenient, repeatable at-home testing without booking a lab visit, and you’ll actually engage with the recommendations it returns.
- SiPhox may be less ideal if your real bottleneck isn’t getting data but deciding on it — or if a decision genuinely needs a confirmatory venous draw or clinician review.
- Verify before you buy. Marker count, turnaround, the recommendation features and price all change — confirm the current details on SiPhox’s own pages.
- An at-home panel is a beginning, not an answer. Some results need a clinician or a confirmatory draw; AMORTAL should never be read as a diagnosis.
Bring your results into a decision, not a dashboard
AMORTAL doesn’t need to be where you run every test. The stronger model is to let a convenient provider like SiPhox do the at-home collection, then use AMORTAL as the longitudinal decision-and-restraint system around those results. Upload a SiPhox report, or enter the markers that matter. AMORTAL turns the result into memory, evaluates whether it’s enough to act on or worth confirming, ranks the next best action, sets a watchlist for the signals to expect, and later checks whether the action actually worked.
Already have results from SiPhox Health? Bring them into AMORTAL and ask: “What should I do next?”
Sources
Provider claims describe what each company publicly advertised when this page was last fact-checked (26 June 2026). Pricing, marker counts, turnaround and recommendation features are volatile — verify on the official pages before purchase.
SiPhox Health — at-home testing, biomarker menu, recommendations and pricing.
SiPhox Health — how the at-home finger-stick collection and processing work.
Educational only — this is not medical advice or a diagnosis. Talk to a licensed clinician about your own numbers, targets, and any treatment decisions.
Frequently asked
Can I use AMORTAL with my SiPhox Health results?
Yes — that's the intended use. SiPhox gives you an at-home, finger-stick panel; you bring those results into AMORTAL by uploading the report or entering the key markers. AMORTAL normalises them into a longitudinal memory, connects them to your goals, wearables and any protocols, and returns one ranked next action rather than a wall of numbers. AMORTAL has no direct SiPhox integration; you bring the data in by upload or manual entry.
Does AMORTAL replace SiPhox Health?
No. They do different jobs. SiPhox is a data source — it runs the at-home collection and returns the panel. AMORTAL is a decision layer that sits on top of whatever results you have. Most people who use both keep SiPhox for convenient at-home retesting and use AMORTAL to decide what each result should change, what to ignore, whether an at-home reading needs confirming, and when to retest.
Does AMORTAL order the test for me?
No. AMORTAL is not a testing company and does not order or sell kits. It works from results you already have — from SiPhox, a clinician, or any other lab. If a decision genuinely needs a test or a confirmatory venous draw you don't have yet, AMORTAL will say so and tell you which one would actually change the decision, rather than encouraging you to test everything.
What does AMORTAL do after my results come in?
It files them into your health memory, activates the standards that apply to you, and produces a Decision Contract: one next best action, the single signal you'd expect it to move, and the window to watch. It also flags when an at-home reading is worth confirming before you act, creates watchlist items for markers worth re-checking later — and will tell you when the right move is to change nothing yet.
When should I retest with SiPhox?
That depends on what you changed and how long that change needs to show up in blood — not on the calendar, and not on how easy the at-home kit makes it. AMORTAL sets an expected window per marker and tells you when a retest would be informative versus premature. Convenient at-home retesting is genuinely useful, but testing too early is one of the most common ways people misread normal variation as a real result.
Is an at-home finger-stick result reliable enough to act on?
Often, yes — for tracking trends. At-home capillary panels are convenient and good for watching a marker over time. But some decisions warrant a confirmatory venous draw or clinician review: a wildly out-of-range value, a single alarming reading, or anything that would change a medication. AMORTAL doesn't run the test, but it flags when an at-home result looks sufficient to act on versus when you should confirm it first — so convenience doesn't turn into overreaction.